Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2022-07-05 AGM Information
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
Results of Annual General Meeting which was held on July 3, 2022
AGM Information Classification · 99% confidence The document explicitly states in the title and body: "BioLineRx reports results of shareholders meeting". It also mentions an attached file named "AGM_-_6-K_isa.pdf". The content is very short (1819 chars) and serves to announce the results of a shareholder meeting, rather than being the full report itself. This strongly indicates an announcement related to the Annual General Meeting (AGM) results. The most specific code for AGM-related results is AGM-R (AGM Information/Results). Although it mentions an attachment, the core subject is the meeting results, making AGM-R more precise than the general RPA or RNS.
2022-07-05 English
6-K
Regulatory Filings
2022-06-28 English
ollaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)
Regulatory Filings Classification · 98% confidence The document explicitly identifies itself as a "FORM 6-K" filed with the "SECURITIES AND EXCHANGE COMMISSION" for the month of June 2022. Form 6-K is a report of a foreign private issuer required under the Securities Exchange Act of 1934. This form is used to report material information that the company is required to disclose to its home country's stock exchange or make public in its home country, or information that is material to investors. It is not one of the specifically defined US periodic reports (like 10-K) or specific event reports (like DEF 14A, ER, etc.). Since Form 6-K is a general regulatory filing requirement for foreign private issuers that doesn't fit neatly into the other specific categories (like AGM-R, 10-K, ER, etc.), the most appropriate classification based on the provided definitions is the general fallback category for miscellaneous regulatory filings. Classification: Regulatory Filings (RNS).
2022-06-28 English
ollaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, dated 28/06/2022. The content announces a 'Collaboration Agreement' regarding a drug development program. Crucially, the text states: 'Attached hereto is a report on*BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC)* *6-K_28-June-22_isa.pdf*'. This structure—a brief announcement stating that a more detailed report (in this case, likely a 6-K filing, which is often used for material events by foreign private issuers) is attached or referenced—fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) nor a standard earnings release (ER). Since it announces the publication of a specific report/document, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2022-06-28 English
6-K
Regulatory Filings
2022-06-16 English
BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer
Board/Management Information Classification · 98% confidence The document header explicitly identifies the filing as a "FORM 6-K" and the submission form type as "6-K". Form 6-K is the standard SEC filing used by Foreign Private Issuers to report material events that occur between required annual (20-F) or semi-annual reports. The content details the appointment of a new Chief Commercial Officer and includes a press release announcing this management change. This type of announcement (change in senior management) directly corresponds to the definition for Board/Management Information (MANG). Although the 6-K is a general regulatory filing, the specific content (management change) allows for a more precise classification based on the provided definitions. Since MANG covers 'Announcement of changes in the company's board of directors or senior management,' this is the most appropriate code, overriding the general 'RNS' fallback.
2022-06-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.